GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » Margin of Safety % (DCF FCF Based)

Ascletis Pharma (HKSE:01672) Margin of Safety % (DCF FCF Based) : N/A (As of Dec. 12, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Ascletis Pharma's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.


Competitive Comparison of Ascletis Pharma's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Ascletis Pharma's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascletis Pharma's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's Margin of Safety % (DCF FCF Based) falls into.



Ascletis Pharma Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascletis Pharma Business Description

Industry
Traded in Other Exchanges
Address
198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. Ritonavir tablets, GANOVO, and ASCLEVIR. It also has other drug candidates in its pipeline in their different stages of development such as ASC22, ASC10, ASC11, and ASC40 among others. Geographically, it operates in Mainland China and other countries.
Executives
Jjw12 Limited
Lakemont Holding Llc
Wu Jinzi Jason 2101 Beneficial owner
Wu Judy Hejingdao 2101 Beneficial owner
Jjw11 Limited
C-bridge Capital Gp, Ltd. 2201 Interest of corporation controlled by you
Fu Wei 2201 Interest of corporation controlled by you
Tf Capital Ii Ltd. 2201 Interest of corporation controlled by you
Tf Capital, Ltd. 2201 Interest of corporation controlled by you
Kang Hua Investment Company Limited 2201 Interest of corporation controlled by you
Yang Dan 2201 Interest of corporation controlled by you

Ascletis Pharma Headlines

No Headlines